Lupin Limited has informed the Exchange regarding a press release dated March 25, 2026, titled "Lupin Receives Tentative Approval from U.S. FDA for Pitolisant Tablets".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lupin has received a tentative approval from the U.S. FDA for its generic Pitolisant Tablets in 4.45mg and 17.8mg strengths, filed via an Abbreviated New Drug Application. The product is a generic version of Wakix®, used for treating conditions related to the approved labeling, and will be manufactured at Lupin's Nagpur facility in India. A 'tentative' approval means the FDA has cleared it on quality and bioequivalence grounds but Lupin cannot launch commercially until existing patent or exclusivity protections on the brand expire. This adds to Lupin's growing portfolio of complex generics in the U.S. market.
Positively signals Lupin's expanding U.S. generic pipeline, but actual revenue contribution is delayed until final approval and market launch. Investors may see this as a medium-term positive rather than an immediate earnings driver.